Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19

Das, Rakha H.; Kotra, Komal; Singh, Pulkit; Loh, Belinda; Leptihn, Sebastian; Bajpai, Urmi

doi:10.1007/s40121-021-00559-8

Cited by 11 publications

(9 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, fungal invasions, such as invasive pulmonary aspergillosis (IPA) and invasive candidiasis (IC), have been reported. 17 …”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, fungal invasions, such as invasive pulmonary aspergillosis (IPA) and invasive candidiasis (IC), have been reported. 17 The patient was transferred to our hospital after a 48-hour admission to the emergency department of another hospital where he had been administered tocilizumab and corticosteroids. After a few days of hospitalization, his renal function deteriorated and four hemofiltration sessions were scheduled, which may have contributed to the presence of opportunistic infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A 71-Year-Old Man From Ecuador With a History of Type 2 Diabetes Mellitus and Severe COVID-19 Pneumonia and Lung Cavitation Associated With Triple Infection With Trichosporon Asahii, Klebsiella Pneumoniae, and Pseudomonas Aeruginosa

Claudett

Briones-Claudett²,

Loor³

et al. 2022

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

Unvaccinated patients with comorbidities that impair the immune function, such as type 2 diabetes mellitus, are more likely to develop severe COVID-19. The COVID-19-associated acute respiratory distress syndrome has raised new concerns in intensive care units globally owing to the presence of secondary fungal infections. We report the case of a 71-year-old man from Ecuador with a history of type 2 diabetes mellitus, severe COVID-19 pneumonia, and lung cavitation associated with triple infections with Trichosporon asahii, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The patient with a history of high blood pressure and type 2 diabetes was admitted to our hospital from a private care center with a diagnosis of COVID-19-associated acute respiratory distress syndrome. On arrival, the patient presented with signs of hypoxemic respiratory failure. During his stay at another hospital, he had received tocilizumab and corticosteroid therapy. Therefore, intubation was performed and mechanical ventilation was initiated. The patient developed a septic shock and renal failure with a glomerular filtration rate of 27.5 mL/min/1.73 m2; therefore, two hemodiafiltration sessions were started. The bronchoalveolar lavage revealed erythematous lesions in the bronchial tree and abundant purulent secretions and erosions in the bronchial mucosa, with a cavitary lesion in the right bronchial tree. The bronchoalveolar lavage samples were used to isolate Trichosporon asahii, Klebsiella pneumoniae, and Pseudomonas aeruginosa carbapenemase class A. Matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) Biotyper mass spectrometry and polymerase chain reaction (PCR) molecular identification were performed. This case report suggested that patients with severe COVID-19 pneumonia, with or without comorbidities, are more susceptible to opportunistic infections.

show abstract

“…Furthermore, fungal invasions, such as invasive pulmonary aspergillosis (IPA) and invasive candidiasis (IC), have been reported. 17 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A 71-Year-Old Man From Ecuador With a History of Type 2 Diabetes Mellitus and Severe COVID-19 Pneumonia and Lung Cavitation Associated With Triple Infection With Trichosporon Asahii, Klebsiella Pneumoniae, and Pseudomonas Aeruginosa

Claudett

Briones-Claudett²,

Loor³

et al. 2022

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

show abstract

“…This is achieved by computational modeling or docking approaches for screening/mining of molecules with potential antifungal activity followed by experimental validation ( Kim et al., 2020 ). Recent studies based on this approach have identified potential antifungal activity with known drugs such as anti-cancer drug (Tamoxifen), anti-rheumatic drug (auranofin), calcium channel blockers (Nisoldipine, nifedipine, felodipine), anti-inflammatory drug (Asprin, ibuprofen, tacrolimus), and cardiovascular drug (Atorvastatin) ( Das et al., 2021 ). Other repurposed drugs such as aripiprazole, miltefosine, benzimidazoles, quinacrine, robenidine, raltegravir, cisplatin, and pitavastatin were shown to inhibit hyphal induction, biofilm formation and offer therapeutic benefits in infected animal models ( Kim et al., 2020 ).…”

Section: Alternate Strategies For Effective Antifungal Therapymentioning

confidence: 99%

“…In addition to these strategies, several antifungal peptides, antifungal enzymes, nanoparticles, synthetic chemicals, small molecule inhibitors, natural products and essential oils have shown promising potential as alternate antifungal agents ( Padmavathi et al., 2020 ; Das et al., 2021 ). However, the use of these agents as standalone or adjuvant antifungal agents should be validated by appropriate assay systems and mammalian cytotoxicity data.…”

Section: Alternate Strategies For Effective Antifungal Therapymentioning

confidence: 99%

Fungal infections: Pathogenesis, antifungals and alternate treatment approaches

Reddy

Padmavathi

Nancharaiah

2022

Current Research in Microbial Sciences

View full text Add to dashboard Cite

“…A falta de sucesso no desenvolvimento de antibióticos destaca a necessidade de acelerar os esforços e explorar abordagens terapêuticas inovadoras para o tratamento de infecções bacterianas, variando de anticorpos para bacteriófagos, peptídeos antimicrobianos, nanopartículas, inibidores de pequenas moléculas e terapias que apoiam a resposta imunológica do paciente e enfraquecem os danos provocados pela bactéria (Das et. al., 2022).…”

Section: A Importância De Novos Antimicrobianosunclassified

Novas abordagens terapêuticas: Compostos antimicrobianos produzidos por algas marinhas

Silva

Calado

Barros

et al. 2022

RSD

View full text Add to dashboard Cite

A resistência bacteriana é um problema de saúde pública global. Recentemente, a Organização Mundial da Saúde classificou essa problemática como prioritária para investimento na prospecção de novos antimicrobianos. Diante da escassez de antimicrobianos eficazes frente a bactérias resistentes, o foco futuro da terapêutica médica e da pesquisa é olhar além dos antimicrobianos tradicionais e buscar alternativas que possam regular a virulência microbiana, bem como a inibição do crescimento. Tendências recentes na pesquisa de drogas de fontes naturais sugerem que as algas, em particular, são promissoras para a descoberta de novas substâncias bioquimicamente ativas. Diante disso, o objetivo deste trabalho é descrever a importância dos estudos dos compostos antimicrobianos que estão presentes nas algas marinhas, visto que, é necessário que haja inovações terapêuticas a fim de poder combater as infecções causadas por bactérias resistentes. A atividade antimicrobiana e antibiofilme de extratos de algas marinhas contra patógenos bacterianos humanos tem sido relatada por estudos recentes, indicando que os extratos de algas marinhas podem representar alternativas terapêuticas diante de bactérias resistentes e da ausência de drogas eficazes para tratamento de infecções causadas por superbactérias. Assim sendo, foi realizada uma revisão bibliográfica de abordagem exploratória, apresentando dados e informações expostas em artigos, revistas e jornais científicos. Foram selecionados 32 artigos compreendidos entres os anos de 2018 a 2021, redigidos nas línguas inglesa e portuguesa. Os dados avaliados foram a importância da produção de novos antimicrobianos, bem como resultados eficazes na utilização de algas marinhas na indústria farmacêutica.

show abstract

Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19

Cited by 11 publications

References 161 publications

A 71-Year-Old Man From Ecuador With a History of Type 2 Diabetes Mellitus and Severe COVID-19 Pneumonia and Lung Cavitation Associated With Triple Infection With Trichosporon Asahii, Klebsiella Pneumoniae, and Pseudomonas Aeruginosa

A 71-Year-Old Man From Ecuador With a History of Type 2 Diabetes Mellitus and Severe COVID-19 Pneumonia and Lung Cavitation Associated With Triple Infection With Trichosporon Asahii, Klebsiella Pneumoniae, and Pseudomonas Aeruginosa

Fungal infections: Pathogenesis, antifungals and alternate treatment approaches

Novas abordagens terapêuticas: Compostos antimicrobianos produzidos por algas marinhas

Contact Info

Product

Resources

About